AngioDynamics (ANGO) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.04
- Estimate
- -$0.11
- Surprise
- +64.7%
- Revenue (period 2026-08-31)
- $80.9M
- Score today
- 5.9/10
Revenue source: xbrl.
How the report landed
AngioDynamics (ANGO) reported a narrower loss than forecast — adjusted EPS of -$0.04 against the -$0.11 estimate (a 64.7% beat on a still-unprofitable quarter).
Coverage in the report window
- AngioDynamics Stock Is Falling Thursday: What's Going On? — benzinga, 2026-10-08
- Crude Oil Gains 5%; PepsiCo Posts Upbeat Q3 Earnings — benzinga, 2026-10-08
- AngioDynamics Q1 2027 Earnings Call: Complete Transcript — benzinga, 2026-10-08
Where TrendMatrix's rating stands now
TrendMatrix currently rates ANGO Sell at 5.9/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +64.7% surprise compares with a +76.3% four-quarter average. Next scheduled report: 2027-01-06.
What argues against it
- Quality below floor (4.0 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $12.09
- Price target
- $16.79
- Stop
- $11.24
- Upside to target
- +38.9%
- Reward-to-risk
- 3.2:1
Model outputs from TrendMatrix’s engine as of 2026-10-28 — shown for context, not personalized investment advice.
ANGO at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $515.6M
- P/E (fwd)
- -108.2
- 52-week range
- $9.39–$16.29
- Off 52-week high
- 25.8%
- RSI (14)
- 62
- Volume vs avg
- 0.16×
- Score today
- 5.9/10